MX366223B - Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. - Google Patents

Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.

Info

Publication number
MX366223B
MX366223B MX2015006548A MX2015006548A MX366223B MX 366223 B MX366223 B MX 366223B MX 2015006548 A MX2015006548 A MX 2015006548A MX 2015006548 A MX2015006548 A MX 2015006548A MX 366223 B MX366223 B MX 366223B
Authority
MX
Mexico
Prior art keywords
repeat domains
binding proteins
against her2
domains against
repeat
Prior art date
Application number
MX2015006548A
Other languages
English (en)
Other versions
MX2015006548A (es
Inventor
Fiedler Ulrike
Strobel Heike
Dolado Igancio
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of MX2015006548A publication Critical patent/MX2015006548A/es
Publication of MX366223B publication Critical patent/MX366223B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)

Abstract

La presente invención se refiere a una proteína vinculante o de unión, recombinante, que comprende al menos un primer y un segundo dominio de repetición, en donde cada uno de dichos dos dominios de repetición se vincula o une a la región extracelular del HER2 y en donde dichos dominios de repetición se vinculan o unen covalentemente.
MX2015006548A 2012-11-30 2013-12-02 Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. MX366223B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195156.0A EP2738180A1 (en) 2012-11-30 2012-11-30 Binding proteins comprising at least two binding domains against HER2.
PCT/EP2013/075290 WO2014083208A1 (en) 2012-11-30 2013-12-02 Binding proteins comprising at least two repeat domains against her2

Publications (2)

Publication Number Publication Date
MX2015006548A MX2015006548A (es) 2015-10-15
MX366223B true MX366223B (es) 2019-07-03

Family

ID=47257683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006548A MX366223B (es) 2012-11-30 2013-12-02 Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.

Country Status (11)

Country Link
US (1) US10370414B2 (es)
EP (2) EP2738180A1 (es)
JP (1) JP6410724B2 (es)
KR (1) KR102290592B1 (es)
CN (1) CN104918959A (es)
AU (2) AU2013351096C9 (es)
CA (1) CA2892747C (es)
HK (1) HK1211297A1 (es)
MX (1) MX366223B (es)
RU (1) RU2664464C9 (es)
WO (1) WO2014083208A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
PL2643349T3 (pl) * 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
WO2014060365A1 (en) * 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
AU2014357292B2 (en) 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH 新規なegfr結合タンパク質
KR102427117B1 (ko) * 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
JP6856938B2 (ja) 2015-07-16 2021-04-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH 新規な免疫グロブリン結合タンパク質およびアフィニティ精製におけるそれらの使用
WO2017013136A1 (en) * 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
DK3325514T3 (da) * 2015-07-20 2019-12-16 Navigo Proteins Gmbh Her2-bindende proteiner baseret på di-ubiquitin-muteiner
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
RU2627215C1 (ru) * 2016-05-24 2017-08-03 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Рекомбинантный таргетный токсин, специфичный к клеткам, экспрессирующим рецептор her2
CN109963864B (zh) 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
CN109790206A (zh) 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
MX2021007283A (es) 2018-12-18 2021-07-15 Navigo Proteins Gmbh Proteinas de union especificas del folr1 novedosas para diagnostico y tratamiento del cancer.
JP7611173B2 (ja) * 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えfap結合タンパク質及びそれらの使用
WO2020245746A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins
CN114222757A (zh) * 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
CA3138805A1 (en) * 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
EP4004054A4 (en) 2019-07-26 2023-10-25 Yuhan Corporation ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODIES AND ITS APPLICATION
IL293698A (en) * 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
JP2023525518A (ja) 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途
US20240279309A1 (en) * 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
US20240317852A1 (en) 2021-03-09 2024-09-26 Molecular Partners Ag Novel darpin based cd33 engagers
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
EP4724460A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd16a binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
NZ511699A (en) 1998-12-02 2003-02-28 Phylos Inc DNA-protein fusions and uses thereof
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
BRPI0510716A (pt) * 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
AU2007223855B2 (en) 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
EA201391607A1 (ru) 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白

Also Published As

Publication number Publication date
EP2925784A1 (en) 2015-10-07
CN104918959A (zh) 2015-09-16
WO2014083208A1 (en) 2014-06-05
EP2925784B1 (en) 2021-02-17
JP6410724B2 (ja) 2018-10-24
RU2664464C9 (ru) 2018-12-19
KR20150091138A (ko) 2015-08-07
WO2014083208A8 (en) 2014-10-30
US10370414B2 (en) 2019-08-06
RU2015120663A (ru) 2017-01-10
RU2664464C2 (ru) 2018-08-17
KR102290592B1 (ko) 2021-08-19
CA2892747A1 (en) 2014-06-05
MX2015006548A (es) 2015-10-15
US20150299265A1 (en) 2015-10-22
AU2013351096C9 (en) 2019-01-31
AU2018256592A1 (en) 2018-11-22
AU2013351096A1 (en) 2015-07-09
WO2014083208A9 (en) 2014-12-24
CA2892747C (en) 2022-07-19
EP2738180A1 (en) 2014-06-04
HK1211297A1 (zh) 2016-05-20
AU2013351096C1 (en) 2018-11-08
JP2015537044A (ja) 2015-12-24
BR112015012436A2 (pt) 2017-09-12
AU2013351096B2 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
MX2015006548A (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
CY1119567T1 (el) Θεραπευτικα πεπτιδια
IN2012DN00640A (es)
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
EA201291065A1 (ru) Антитела против vla-4
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12012502115A1 (en) Modified binding proteins inhibiting the vegf-a receptor interaction
PH12013502024A1 (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
BR112014019579A2 (pt) Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
NZ700891A (en) 4-1bb binding molecules
MX2015011075A (es) Peptidos terapeuticos.
UA110049C2 (uk) ЛІКУВАННЯ ОСТЕОАРТРИТУ ІМУНОГЛОБУЛІНОВИМ ЗВ'ЯЗУВАЛЬНИМ БІЛКОМ З ПОДВІЙНИМ ВАРІАБЕЛЬНИМ ДОМЕНОМ, ЩО ЗВ'ЯЗУЄ IL-1α І IL-1β
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
EA201690314A1 (ru) Анти-garp-белок и его применения
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12014501818A1 (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2015013803A (es) Proteina de fusion de enlace al cartilago.
MX2011008749A (es) Variantes de union a anti-albumina de suero mejoradas.
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
NZ700274A (en) Anti-pdgf-c antibodies
PH12016500111A1 (en) An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn

Legal Events

Date Code Title Description
FG Grant or registration